Vascular endothelial growth factor: an essential neurotrophic factor for motoneurons?

Vascular endothelial growth factor (VEGF), an angiogenic factor with neuroprotective effects: The VEGF was initially characterized by its vasculogenic and angiogenic activities and its capacity to promote vascular cerebrospinal fluid samples et al., 2000). VEGF is also known as VEGF-A and is the prototype member of a related group of five trophic factors, VEGF-B, VEGF-C, VEGF-D and placental growth factor (PIGF, Lange et al., 2016). Interestingly, VEGF-B shares a high degree of homology with VEGF but, in contrast to VEGF, has low angiogenic activity and is not a trophic factor for neurons. VEGF-C, VEGF-D and VEGF-E are named VEGFR-1 and VEGFR-2, and also to the coreceptor neuropilin-1. By contrast, VEGF-B only binds to the tyrosine kinase receptor VEGFR-1 and also to the coreceptor neuropilin-1 (Lange et al., 2016).

Nowadays, it is emerging that, in addition to its vascular actions, VEGF also has a significant impact on neurons by protecting them from a disease. Thus, the administration of VEGF, both in vitro and in vivo through different delivery procedures, prevents or delays the death of neurons exposed to different types of insult (Lange et al., 2016). Since the knockout mice for VEGF is not viable, leading to embryonic lethality due to its insufficient development of the vascular system, cardiovascular components as well as the tonic and the phasic components of the discharge are returned to the experimental model. It should be mentioned that although extracocular motoneurons, located in the abducens, trochlear and oculomotor nuclei, are more resistant to amyotrophic lateral sclerosis, they also exhibit some signs of degeneration and cell death at later stages of the disease.

Abducens motoneurons innervate the extraocular lateral rectus muscle. Their discharge correlates with eye movements in the horizontal plane. These motoneurons show a typical tonic-phasic firing pattern, thus having eye position and eye velocity sensitivities. Following axotomy, the discharge of abducens motoneurons shows several alterations such as an overall reduction in firing rate and a significant reduction in eye position and velocity sensitivities. Moreover, axotomy is followed by the withdrawal of synaptic boutons and a reduction in the efficacy of synaptically-driven signals (Davis-López de Carrizosa et al., 2009, 2010). Our recent study (Calvo et al., 2018) indicates that VEGF administration at the time of axotomy completely prevents the lesion-induced alterations in the discharge pattern as well as the synaptic stripping. If VEGF is delayed, not axotomy, this factor is able to recover the physiological activity of abducens motoneurons (both the tonic and the phasic components) and their synaptic inputs.

Figure 1 Schematic diagram comparing the results obtained after different neurotrophic factor administration on axotomized abducens motoneurons.

In each panel, from top to bottom: experimental situation, eye position, and associated firing rate. (A) Control: motoneurons show a typical tonic-phasic discharge proportional to eye position and velocity. (B) Axotomy decreases the discharge, affecting both the tonic and the phasic components. (C) Brain-derived neurotrophic factor (BDNF) administration recovers essentially the tonic firing. (D) Neurotrophin-3 (NT-3) treatment restores basically the phasic activity. (E) Nerve growth factor (NGF) increases both the tonic and the phasic components as well as discharge variability over control values. (F) Vascular endothelial growth factor (VEGF) treatment completely recovers the firing pattern of axotomized motoneurons to control values.
Vascular endothelial growth factor: an essential neurotrophic factor for motoneurons?

Calvo PM, Pastor AM, de la Cruz RR (2018) Vascular endothelial growth factor: an essential neurotrophic factor for motoneurons? Neural Regen Res 13(7):1181-1182. doi:10.4103/1673-5374.235024

It has been hypothesized that VEGF can mediate its trophic actions by two possible mechanisms: i) acting as an angiogenic factor, VEGF can increase the supply of oxygen and nutrients to lesioned motoneurons, and ii) as a direct neurotrophic factor for motoneurons (Oosthuyse et al., 2001; Azouz et al., 2004). It has been demonstrated that VEGF only induces angiogenic response in the central nervous system after the administration of extremely large doses. Thus, a dose-dependent study in ischemic rat brain has shown that low (2 µg/7 days) and intermediate (8 µg/7 days) doses of VEGF are not followed by angiogenesis, whereas a high dose (60 µg/7 days) does induce a powerful angiogenic response (Manoointikwongsa et al., 2004). Most of the authors who have applied VEGF exogenously to damaged neurons have used doses close to the low one (2 µg/7 days; Tovar-y-Romo et al., 2007; Lange et al., 2016; Calvo et al., 2018) and have found neuroprotective effects. Altogether, it can be concluded that the neuroprotective and synaptotrophic effects of VEGF are due to a direct action on neurons.

VEGF-B is a neuroprotective and non-angiogenic: There is less information regarding the effects of VEGF-B on damaged neurons as compared to VEGF-A. However, recent evidence points to different neuroprotective role of VEGF-B in degenerating motoneurons, with the advantage, in relation to VEGF, of not producing vascular side effects, such as inflammation and tissue edema (Poeseen et al., 2008). We have also checked the effects of VEGF-B administration to axotomized abducens motoneurons using the same experimental approach as described above. We found that VEGF-B treatment also prevented axotomy-induced alterations (Calvo et al., 2018). This finding is of great clinical relevance because the angiogenic and permeability-promoting activity of VEGF precludes unrestricted delivery at high doses, in contrast, VEGF-B does not induce any vascular side effects, and exerts similar neurotrophic effects with a greater safety, therefore, providing an attractive alternative to VEGF for the treatment of motoneuron diseases.

VEGF neurophysiologically actions mediated through its receptors: VEGF binds to two tyrosine kinase receptors, VEGFR-1 and VEGFR-2. Both receptors are present in abducens motoneurons. We found that the selective blockage of VEGFR-2 with the inhibitor SU 1498 prevented the full recovery of abducens motoneuron discharge after axotomy during spontaneous, but not during vestibularly-induced, eye movements (Calvo et al., 2018). These data are in congruence with previous findings indicating that both the vascular and neural effects induced by VEGF are mediated mainly through VEGFR-2 (Lange et al., 2016). On the other hand, VEGF-B only binds to VEGFR-1 and we found that VEGF-B prevented axotomized motoneurons to enter into an axotomy-like mode of discharge accompanying recovery of control during both spontaneous and vestibularly-induced eye movements (Calvo et al., 2018). Since spontaneous and vestibularly-driven responses arise from different sources ofafferent to abducens motoneurons, our data suggest that signaling through VEGFR-1 or VEGFR-2 could mediate synaptic actions preferentially on different synaptic inputs. VEGF and VEGF-B can also bind to another membrane protein named neuropilin-1. A widely accepted mechanism of action of neuropilin-1 is the formation of VEGF-dependent complexes of VEGFR-1 or VEGFR-2 with neuropilin-1. Through these complexes, neuropilin-1 would act as a co-receptor of VEGFR-1 or VEGFR-2, enhancing the signaling activity and biological function of VEGF. However, other studies suggest the possibility that neuropilin-1 can signal independently of VEGFR-1 or VEGFR-2 acting as a receptor by itself (Lange et al., 2016). Abducens motoneurons express neuropilin-1 so it would be interesting to analyze the possible physiological role of neuropilin-1 in our model.

Conclusions and future perspectives: The trophic theory of neural connections postulates that neurons are strictly dependent on neurotrophic factors, mainly arising from target tissue, for both survival and the maintenance of a normal functional state. After the discovery of the first neurotrophic factor, NGF, it was soon established that this molecule was crucial for postganglionic sympathetic neurons to survive and to exhibit a proper structure/function. In contrast, for decades, neuroscientists have been looking for a specific neurotrophic factor that could be crucial for motoneurons. However, the list of trophic molecules with beneficial effects on motoneurons is extensive, and there is still no consensus about any particular factor as being the main neurotrophic molecule for this neuronal type. We hypothesize that VEGF might be that molecule acting as an essential neurotrophic factor for motoneurons. According to our data, it is the only neurotrophic factor among all those tested in our experimental model able to prevent and recover completely the firing alterations and synaptopathic loss induced by axotomy in motoneurons (Davis-López de Carrizosa et al., 2009, 2010; Calvo et al., 2018). Moreover, data obtained by other authors (Oosthuyse et al., 2001; Azouz et al., 2004; Tovar-y-Romo et al., 2007; Lange et al., 2016; Wang et al., 2016) indicate that VEGF is the only neurotrophic factor studied to date whose deficit is followed by motoneuron degeneration while its administration is able to rescue degenerating motoneurons from cell death. If our hypothesis is correct, then it would be expected that the blockage of VEGF in control intact animals should lead to motoneuron alterations in synaptic inputs and firing pattern similar to those found after axotomy. VEGF blockage could be performed either by using virus vectors carrying the sequence of the VEGF gene or by inhibiting VEGF gene expression, or pharmacologically following the administration of VEGF neutralizing antibodies. This prospect would reveal the likely significant role played by VEGF in motoneuron physiology and provide valuable information regarding the potential use of VEGF as a therapeutic agent for the treatment of damaged or diseased motoneurons.

This work was supported by Ministerio de Economía y Competitividad-FEDER (Grant reference: BFU2015-64515-P) in Spain. PMC was a scholar of MEC (BES-2016-077912) in Spain.

Paula M. Calvo, Angel M. Pastor,*, Rosa R. de la Cruz
Departamento de Fisiología, Facultad de Biología, Universidad de Sevilla, Sevilla, Spain
*Correspondence to: Angel M. Pastor, Ph.D., ampastor@us.es.
Received: 06-0000-6213-7454 (Angel M. Pastor)
Accepted: 2018-05-24
doi: 10.4103/1673-5374.235024
Copyright transfer agreement: The Copyright License Agreement has been signed by all authors before publication.
Plagiarism check: Checked twice by Thenticate.
Peer review: Externally peer reviewed.
Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution Non-Commercial Share-Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

References
Azouz M, Ralph GS, Storksebaam E, Walmalee LE, Mitrophanas KA, Kingsman SM, Carmeliet P, Manzarakis ND (2004) VEGF delivery with retrogradely transported lentivirus prolongs survival in a mouse ALS model. Nature 429:413-417.
Calvo PM, de la Cruz RR, Pastor AM (2018) Synaptic loss and firing alterations in Axotomized Motoneurons are restored by vascular endothelial growth factor (VEGF) and VEGF-B. Exp Neurol 304:67-68.
Davos-López de Carrizosa MA, Morado-Díaz CJ, Mercruende S, de la Cruz RR, Pastor AM (2010) Nerve growth factor regulates the firing patterns and synaptic composition of motoneurons. J Neurosci 30:8308-8319.
Davos-López de Carrizosa MA, Morado-Díaz CJ, Tena JJ, Benitez-Temitio B, Pecero ML, Mercruende SR, de la Cruz RR, Pastor AM (2009) Complementary actions of BDNF and neurotrophin-3 in influencing firing patterns and synaptic composition of motoneurons. J Neurosci 29:575-587.
Lange C, Storksebaam E, de Almodovar CR, Dewerchlin M, Carmeliet P (2016) Vascular endothelial growth factor: a neurovascular target in neurological diseases. Nat Rev Neuro 12:439-454.
Manoointikwongsa PS, Schultz RL, McCreery DB, Whitter EF, Lyden PD (2004) Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis. J Cereb Blood Flow Metab 24:693-702.
Oosthuyse B, Moons L, Storksebaam E, Beck H, Noyens D, Brusselmans K, Van Dorpe J, Hellings P, Gorislink M, Heymans S, Theilmeier G, Dewerchlin M, Laudenbach V, Verrynel P, Raat H, Acker T, Vleminckx V, Van Den Bosch L, Cashman N, Fujiwasa H, et al. (2001) Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28:131-138.
Poeseen K, Lambrechts D, Van Damme P, Dhondt J, Bender F, Frank N, Bogaert E, Claes B, Heymann L, Kerschh H, Rau K, Tywa M, Eriksson U, Shiblya M, Nuydens R, Van Den Bosch L, Meert T, D’hooge R, Sendtner M, Robberecht W, et al. (2008) Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration. J Neurosci 28:10451-10459.
Sathasivam S (2008) VEGF and Neurodegeneration. Exp Neurol 212:67-77.
Tovar-y-Romo LB, Zepeda A, Tapia R (2007) Vascular endothelial growth factor prevents paralysis and motoneuron death in a rat model of excitotoxic spinal cord neurodegeneration. J Neurotrauma Exp Neurol 24:913-922.
Wang Y, Duan W, Wang W, Di W, Liu Y, Liu Y, Li H, Lin H, Cui C, Li, D, Dong H, Li C (2016) sCA1-V9: VEGF prolongs the survival of transgenic ALS mice by promoting activation of M2 microglia and the PI3K/Akt pathway. Brain Res 1648:1-10.
Yankee Posis GD, Davis S, Gale N. W. (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242-248.

1182